Olr831 inhibitors represent a specific class of chemical compounds that have garnered attention within the realm of molecular biology and biochemistry due to their capacity to modulate the function of the Olr831 receptor. Olr831, a member of the olfactory receptor family, is a G-protein-coupled receptor (GPCR) primarily involved in the detection of odorants. The inhibitors targeting Olr831 are designed to interact with the receptor in a manner that diminishes or completely blocks its ability to bind with its natural ligands, thus impeding the subsequent signal transduction pathways. These inhibitors typically exhibit high specificity and affinity towards the Olr831 receptor, allowing for precise modulation of olfactory signal processing. The structural diversity among Olr831 inhibitors is significant, with compounds ranging from small organic molecules to more complex synthetic derivatives, each tailored to fit the unique binding pocket of the Olr831 receptor.
The development and study of Olr831 inhibitors involve extensive use of computational modeling and structure-activity relationship (SAR) analysis to understand the intricate interactions at the molecular level. Crystallography and other advanced spectroscopic techniques are often employed to elucidate the binding modes and conformational changes induced by these inhibitors. Such detailed structural insights are critical for the rational design of more potent and selective inhibitors. Furthermore, the synthesis of these inhibitors requires sophisticated organic chemistry methodologies to achieve the desired molecular configurations and functionalities. Research in this area also explores the kinetic and dynamic properties of these inhibitors, including their binding kinetics, receptor occupancy, and potential allosteric effects. The comprehensive understanding gained from these studies not only enhances the fundamental knowledge of Olr831 receptor biology but also paves the way for innovative approaches in receptor modulation and signal transduction research.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Non-selective beta-adrenergic receptor blocker that can inhibit GPCR signaling, potentially impacting similar receptors like Olr831. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $122.00 $235.00 $520.00 $979.00 $1500.00 | 2 | |
Blocks beta-adrenergic receptors and can inhibit associated GPCR activity, potentially affecting Olr831 signaling. | ||||||
NF449 | 627034-85-9 | sc-478179 sc-478179A sc-478179B | 10 mg 25 mg 100 mg | $199.00 $460.00 $1479.00 | 1 | |
Potent Gs alpha subunit inhibitor, possibly impacting GPCR signaling pathways including those involving Olr831. | ||||||
YM 254890 | 568580-02-9 | sc-507356 | 1 mg | $500.00 | ||
Selective Gq inhibitor, could disrupt GPCR-mediated signaling, thereby affecting Olr831 function. | ||||||
KT 5720 | 108068-98-0 | sc-3538 sc-3538A sc-3538B | 50 µg 100 µg 500 µg | $97.00 $144.00 $648.00 | 47 | |
Protein kinase A inhibitor, can disrupt cAMP pathways, possibly influencing Olr831-mediated signaling. | ||||||
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $442.00 | 3 | |
Inactivates Gi/o proteins, could disrupt GPCR signaling pathways, affecting Olr831 activity. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $223.00 | 8 | |
Protein kinase C inhibitor, potentially influencing signaling pathways related to Olr831. | ||||||
Clozapine | 5786-21-0 | sc-200402 sc-200402A | 50 mg 500 mg | $68.00 $357.00 | 11 | |
Antagonizes various GPCRs, could indirectly affect Olr831 signaling. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
Broad spectrum GPCR antagonist, could inhibit various GPCR activities including Olr831. | ||||||
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $149.00 $210.00 $714.00 $2550.00 $10750.00 $21410.00 $40290.00 | 5 | |
Inhibits G protein interactions, possibly affecting Olr831 function. | ||||||